Leuven, Belgium - October 22, 2020 - 6.45 PM CET, ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative immune-oncology treatments, today presents its strategy directed at boosting T cell migration, infiltration and activity into solid tumors, and announces that it has reached preclinical proof of concept and has entered the lead optimization phase with its proprietary CCR8 Treg program.

Visit link:
ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors Announcing First Preclinical Proof of Concept in Proprietary...

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, October 29, 2020 to report its third quarter 2020 financial results and business highlights.

Read more from the original source:
Evelo Biosciences to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020

Agreement adds OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria

Original post:
Retrophin Announces Agreement to Acquire Orphan Technologies

BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the third quarter ended September 30, 2020, and provide an update on recent business highlights, on November 5, 2020.

Read more from the original source:
X4 Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020

STOUGHTON, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.

Go here to see the original:
Collegium to Host Conference Call to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update

SANTA CLARA, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease will webcast an investor update at the virtual VIVA20 on Saturday, November 7 at 11:00 a.m. eastern time. Dr. William Gray, M.D., FACC, FSCAI, Chief of the Division of Cardiovascular Disease at Main Line Health, Wynnewood, PA; Co-Principal Investigator of DISRUPT PAD III will present the results of the PAD III study and then will be joined by Dr. Sarang Mangalmurti, M.D., Interventional Cardiologist and Endovascular Specialist, Bryn Mawr Hospital – Main Line, Doug Godshall, Chief Executive Officer of Shockwave and Keith Dawkins, Chief Medical Officer of Shockwave to discuss the results and answer questions from investors about the study.

Link:
Shockwave Medical Announces VIVA20 Investor Update and Conference Call Discussing Third Quarter 2020 Results

– Received FDA Orphan Drug and Fast Track designations for novel glioblastoma radiotherapy –

Link:
Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

GUILFORD, Conn., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that John D. Vandermosten, CFA, Biotechnology Analyst of Zacks Small Cap Research division at Zacks Investment Research and his team (“Zacks”) has initiated analyst coverage on Bioasis Technologies Inc.

Continue reading here:
Bioasis Announces Analyst Coverage Initiated by Zacks Investment Research

MONTREAL, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that management will be presenting at the following upcoming virtual investor conferences.

See more here:
Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020

RESEARCH TRIANGLE PARK, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2020 financial results on Thursday, November 5, 2020.

Follow this link:
BioCryst to Report Third Quarter 2020 Financial Results on November 5

REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released after market close on Thursday, November 5, 2020. Starting at 4:30 p.m. EST, Coherus’ management team will host a conference call to discuss financial results and provide a general business update.

More:
Coherus BioSciences to Report Third Quarter Financial Results on November 5th

California cannabis industry leader adds veteran executive and strategic advisor to leadership team California cannabis industry leader adds veteran executive and strategic advisor to leadership team

See the original post:
Indus Holdings, Inc. Welcomes Bruce Gates to Board of Directors; Announces Results of Annual Shareholder Meeting

PRINCETON, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences Holdings Limited (KBP Biosciences), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative therapeutics for the treatment of major diseases with large underserved patient populations, today announced upcoming data to be presented at the American Society of Nephrology (ASN) Annual Meeting, being held in a virtual format from October 22-25, 2020. Frederic Jaisser, Head of the Physiology Department, Cordeliers Research Center, Research Director, INSERM, is presenting an abstract entitled: “The non-steroidal mineralocorticoid receptor antagonist KBP-5074 limits albuminuria with improved efficacy and safety compared to eplerenone.”

Continued here:
KBP Biosciences Announces Data Presentation at the American Society of Nephrology Annual Meeting

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2020 financial results and corporate update conference call and live audio webcast on Thursday, October 29th at 8:30 a.m. EDT.

Read the original:
Genocea to Host Third Quarter 2020 Corporate Update Conference Call & Webcast

Milestone payment further bolsters Innate’s cash position

View original post here:
First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca

REGULATED INFORMATION

See the original post:
Bone Therapeutics SA: Information on the total number of voting rights and shares

REGULATED INFORMATION

More here:
Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA

Read the original post:
Nicox Selects Development Candidate in a New Class of NO-mediated Intraocular Pressure (IOP) Lowering Agents

Augustinus Bader on his revolutionary approach to skincare

The mind behind the most coveted products in beauty discusses thescience behind the brand

When Augustinus Bader first launched The Cream in 2018, it was hailed as a miracle. In a matter of weeks, it could transform any skin type within any age range, dispelling wrinkles, redness, dryness, scaring, visible pores, sagginess, and practically every other skin concern it would usually take a shelf load of serums to combat. While miraculous, magical, and other mystical attributions caneasily, and quite fairly, be applied to Augustinus Bader products, the real genius of the brand comes down to pure science.

The Augustinus Bader skincarebrand was the by-product of its namesakes development of medical-grade cream, which could heal severe burn injuries to an extent that was previously only possible through skin grafts. Professor Bader, a stem cell and biomedical scientist at Leipzig University, was hoping to get the cream backed by a pharmaceutical company but, in the words of his business partner Charles Rosier, clinical trials cost tens of tens of millions of dollarsand the majority of accidents around burns happen to children, often in third-world countries. For a pharmaceutical company, when the outcome is not necessarily the most profitable outcome, theres less interest.

Inspired to make Baders cream widely available, Rosier encouraged the Professor to translate the principles of his burn cream into skincare. In my mind, I thought, if we create a cream thats superior to whats on the market and its a big success, then he can focus on is research and we can finance the clinical trial.

Baders cream centred around one, revolutionary hypothesisthat the body already possesses all of the stem cells it needs to regenerate itself. The problem, when it comes to the skins inability to heal from severe injuries or just the everyday effects of ageing, is that the bodys ability to trigger those regenerative cells has been impeded.

Bader developed this hypothesis based on two observations. First, that the size of the wound affects the bodys ability to heal. Asmall paper cut heals quickly, while a large scale burn takes time to heal and often leaves scar tissue. Secondly, the body automatically knows where the site of an injury is. When you cut your left hand, your body immediately starts sending cells to the area of the cut so that the skin can rebuild. Yet,the same tissue would never rebuild on your right hand because it rebuilt on your left. Only where there is a wound is the body rebuilding.

In Baders words, If the cut is super small, you would have a small distance between the edges of the cut skin and the cells can still communicate over this small distances through the hand, and would close the wound. But if you burn your hand, the cells would be dying and the signal response cannot arrive at this injury. The response is totally different, the small cut heals perfectly, while on the other side the big injury kills this confirmation.

So the basis of [my] hypothesis is that this is probably just the absence of specific molecules that cannot arrive to the site of the injury because cells are dying or are blocked. So many, many years ago I started trying to find solutions to this problem because genetically speaking were the same human being, why would we have these limitations, why would we have these problems? It doesnt make any sense.

I thought, why not try to replace what the cells would be doing if they were present? That triggering complex, which singles the cells to respond to the injury, or, when it comes to skincarewrinkles, is the secret, miracle likeelement of Baders cream.

Unlike most skincare, which just changes the outside surface of the skin, Baders skincare works from the inside out, transforming the bodys internal, cellular communication for exterior changes. I think ageing is just a lack of repair, a lack of regeneration. Skin is a living organism, which has to be remodelled, meaning repaired a little bit everyday. But you can accelerate this repair lead.

Theres something super, super sensitive inside of you, which are these cells that sense the microenvironment and respond to the need. So the cream, in a way, is only a toolbox, which helps your stem cells when they sense this need to interact more appropriately.

This new approach to the effects of ageing is a revolution in skincare that, no doubt, heralds the beginning of a new science-driven, cellular-focused trend in the industry.

This year, Bader has launched a number of additional products to his line beyond The Cream and its companion The Rich Cream. The new additions include a Cleansing Gel, Face Oil, Body Cream and, as of today, Cleansing Balm with more releases set for the next year.

See the rest here:
Augustinus Bader on his revolutionary approach to skincare - Wallpaper*

Getting up there in years comes with its drawbacks and benefits, and the onset of facial lines and volume loss that comes tends to be at the top of the list as one of its main disadvantages. You can count facial aging right up there with the onslaught of back pain and the occasional grey hair turning into a full head of silver. To soften those where did they come from facial lines and give skin a more youthful glow, these anti-agers target the main offenders: wrinkles and uneven skin tone and texture.

2/8

Glycolipids in Dr. Loretta Intense Replenishing Serum ($70) trash moisture on the skin surface to help hydrate skin while the antioxidant lipochroman combats free radicals and protects from harmful UV light, leaving skin looking plump, smooth and rejuvenated.

3/8

Apply a layer of Augustinus Bader The Face Oil ($230) morning and night. Utilizing Professor Baders TFC8 technology, the oil promotes cellular renewal, which helps smooth skin texture and reduce the look of fine lines and wrinkles.

4/8

The name says it all with Zo Skin Healths Firming Serum ($235). Lightweight and tolerable for even sensitive skin types, this anti-ager includes the brands ZCORE complex which consists of a synthetic tetrapeptideand sweet yellow clover to help strengthen skin laxity. Plant stem cells provide plant stem cell complex provides powerful antioxidant protection while sodium DNA helps stimulate cell repair and reduce inflammation.

5/8

Harnessing the brands signature ingredient, La Prairies Skin Caviar Liquid Lift ($690) blends two types of caviar, Premiere and Absolute, into a milky emulsion to deliver the perfect dose of serum that promises firmer skin and enhanced elasticity.

6/8

Bioeffect Limited Edition EGF Serum ($495) is said to have twice the original EGF formulas anti-aging benefits due to its inclusion of a rare black barley that is grown at the brands state-of-the-art greenhouse in Iceland. The EGF stands for Epidermal Growth Factor, which in this serum is totally plant derived and signals skin cells to prompt collagen and elastin production. The unique bottle was designed by Icelandic artist Shoplifter and is made from black obsidian.

At NewBeauty, we get the most trusted information from the beauty authority delivered right to your inbox

Find a NewBeauty "Top Beauty Doctor" Near you

Link:
8 Skin-Boosting, Anti-Aging Treatments for Generation Xers and Beyond - NewBeauty Magazine